Dopamine

The dosage of Dopamine must be individualized based on the patient's clinical response and hemodynamic parameters, such as blood pressure, heart rate, and urine output. It is always administered via a controlled infusion pump to ensure precise delivery.

• Initial Starting Dose: Typically 2 to 5 mcg/kg/min. This low starting point allows the clinician to assess the patient's sensitivity to the drug.
• Titration: The dose is increased in increments of 5 to 10 mcg/kg/min at intervals of 10 to 30 minutes until the desired hemodynamic response is achieved.
• Maintenance Dose: Most patients respond to infusion rates between 5 and 20 mcg/kg/min.
• Maximum Dose: While some critical situations may require doses exceeding 50 mcg/kg/min, such high doses are associated with a significantly increased risk of serious arrhythmias and peripheral ischemia. If doses above 20 mcg/kg/min are required, healthcare providers often consider adding a second vasopressor.

Dopamine is used in pediatric and neonatal populations, particularly for shock and low cardiac output states. However, the FDA notes that the safety and effectiveness of Dopamine in children have not been established through controlled clinical trials.

• General Pediatric Range: 1 to 20 mcg/kg/min, titrated to effect.
• Neonatal Use: Often started at lower doses (1-5 mcg/kg/min) due to the immaturity of the sympathetic nervous system and varying receptor sensitivity in newborns.

Renal Impairment

No specific dose adjustment is required for patients with renal failure, as the drug is primarily metabolized by enzymes (MAO and COMT) rather than excreted unchanged by the kidneys. However, close monitoring of urine output and electrolyte balance is mandatory.

Hepatic Impairment

Because the liver is a site of metabolism for Dopamine, patients with severe hepatic impairment may experience a slightly prolonged effect. Dosing should be cautious and guided by real-time hemodynamic monitoring.

Elderly Patients

Geriatric patients are generally more sensitive to the effects of catecholamines. There is a higher risk of developing cardiac arrhythmias (irregular heartbeats) or myocardial ischemia (lack of oxygen to the heart) in this population. Lower starting doses and slower titration are recommended.

Dopamine is never 'taken' by the patient; it is administered by trained medical professionals in a hospital setting (usually the ICU, ER, or OR).

• Route: Continuous intravenous (IV) infusion.
• Site Selection: It is strongly recommended that Dopamine be administered into a large vein (such as a central line) to minimize the risk of extravasation (the drug leaking into the surrounding tissue), which can cause severe tissue necrosis (cell death).
• Monitoring: Patients receiving Dopamine must undergo continuous electrocardiogram (ECG) monitoring, frequent blood pressure checks (often via an arterial line), and hourly monitoring of urine output.
• Storage: Unused vials should be stored at controlled room temperature (20°C to 25°C). Diluted solutions are typically stable for 24 hours.

Because Dopamine is administered as a continuous infusion in a controlled medical environment, the concept of a 'missed dose' does not apply in the traditional sense. If an infusion is accidentally interrupted, the patient's blood pressure may drop rapidly due to the drug's 2-minute half-life. Medical staff must immediately restart the infusion and stabilize the patient.

An overdose of Dopamine typically manifests as an excessive increase in blood pressure and the development of cardiac arrhythmias.

• Symptoms: Severe headache, dangerously high blood pressure (hypertension), chest pain, shortness of breath, and palpitations.
• Management: Because Dopamine has a very short half-life, the first step in managing an overdose is to reduce the rate of infusion or temporarily discontinue it. If blood pressure remains dangerously high, short-acting alpha-adrenergic blocking agents (like phentolamine) may be administered.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. This information is for educational purposes and does not replace professional medical judgment.

Due to its potent physiological effects, side effects are common during Dopamine therapy. Patients and clinicians should expect the following:

• Tachycardia (Rapid Heart Rate): As a beta-1 agonist, Dopamine frequently increases the heart rate. This may feel like a racing or pounding heart.
• Palpitations: An awareness of the heartbeat, often described as 'skipping a beat' or 'thumping' in the chest.
• Nausea and Vomiting: Stimulation of dopaminergic receptors in the chemoreceptor trigger zone of the brain can induce significant gastrointestinal upset.
• Headache: Often resulting from the rapid changes in systemic blood pressure.
• Dyspnea (Shortness of Breath): May occur as the heart works harder to pump blood or due to changes in pulmonary vascular pressure.

• Ectopic Beats: Extra heartbeats that can be seen on an ECG monitor.
• Angina Pectoris (Chest Pain): Occurs when the heart's demand for oxygen (increased by Dopamine) exceeds the supply, particularly in patients with existing coronary artery disease.
• Hypotension: Paradoxically, at very low doses, vasodilation may occasionally cause a slight drop in blood pressure before the inotropic effects take hold.
• Vasoconstriction: Excessive narrowing of the blood vessels, leading to cold extremities or 'goosebumps' (piloerection).

• Aberrant Ventricular Conduction: Serious disturbances in the electrical signaling of the heart.
• Bradycardia: A slow heart rate, which is rare but can occur as a reflex response to very high blood pressure.
• Azotemia: An increase in nitrogenous waste products in the blood.
• Widening of the QRS Complex: A change in the heart's electrical pattern that may precede dangerous arrhythmias.

> Warning: Stop taking Dopamine and call your doctor immediately if you experience any of these. In a hospital setting, nursing staff will be monitoring for these signs constantly.

• Ventricular Arrhythmias: Life-threatening heart rhythms (like ventricular tachycardia or ventricular fibrillation) that require immediate electrical or chemical intervention.
• Peripheral Ischemia and Gangrene: At high doses, Dopamine can cause such severe vasoconstriction in the hands and feet that blood flow is cut off. This can lead to tissue death (gangrene), especially in patients with pre-existing vascular disease (like diabetes or Buerger's disease).
• Anaphylaxis: Severe allergic reactions, including swelling of the face, tongue, or throat, and difficulty breathing.
• Extravasation Injury: If the IV fluid leaks into the skin, the area may become cold, hard, and eventually turn black (necrosis). This is a medical emergency requiring phentolamine injection into the site.

Dopamine is intended for short-term, acute stabilization. Long-term use (days to weeks) is rare and can lead to:

• Tachyphylaxis: A rapidly diminishing response to the drug, requiring higher and higher doses to achieve the same effect.
• Myocardial Damage: Prolonged exposure to high levels of catecholamines can cause direct 'stress' damage to the heart muscle fibers.
• Hypovolemia Masking: Dopamine can maintain blood pressure while the patient's actual fluid volume remains dangerously low, leading to sudden collapse when the drug is stopped.

FDA Black Box Warning: Extravasation

To prevent sloughing and necrosis in ischemic areas, the infusion should be directed into a large vein whenever possible. The infusion site should be monitored continuously for signs of extravasation. If extravasation occurs, the area should be infiltrated as soon as possible with 10 to 15 mL of saline solution containing from 5 to 10 mg of phentolamine, an adrenergic blocking agent. A syringe with a fine hypodermic needle should be used, and the solution should be liberally infiltrated throughout the ischemic area. Prompt phentolamine infiltration will result in immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours.

Report any unusual symptoms to your healthcare provider immediately. In the ICU, your vital signs are monitored every few minutes to ensure your safety.

Dopamine is a high-alert medication that requires intensive monitoring. It should only be used after adequate fluid resuscitation (giving IV fluids) has been attempted, unless the patient is in cardiogenic shock. Using Dopamine in a patient who is 'empty' (severely dehydrated or bleeding) can cause severe organ damage because the drug forces the heart to work harder without enough blood to pump.

Extravasation Risk: As detailed in the side effects section, Dopamine can cause severe tissue death if it leaks out of the vein. Healthcare providers must use a central venous catheter or a very large peripheral vein and check the site every hour. Phentolamine must be available on the unit as an immediate antidote for local tissue ischemia.

• Allergic Reactions / Sulfite Sensitivity: Many Dopamine formulations contain sodium metabisulfite, a sulfite that may cause anaphylactic-type symptoms and life-threatening asthma episodes in susceptible individuals. This is more common in people with asthma.
• Cardiovascular Risks: Dopamine significantly increases myocardial oxygen consumption. It must be used with extreme caution in patients with recent heart attacks or known coronary artery disease, as it can trigger further heart muscle damage or dangerous arrhythmias.
• Hypovolemia: Before starting Dopamine, any depletion in blood volume (hypovolemia) should be fully corrected with whole blood or plasma expanders. If blood pressure is maintained by Dopamine without volume replacement, vital organ perfusion may actually decrease.
• Peripheral Vascular Disease: Patients with a history of Raynaud's disease, diabetic endarteritis, or arterial embolism are at a much higher risk of developing gangrene in their fingers and toes when given Dopamine.

Patients on Dopamine require 'Level 1' monitoring, which includes:

• Continuous ECG: To detect arrhythmias immediately.
• Invasive Hemodynamics: Often an arterial line for beat-to-beat blood pressure monitoring.
• Urine Output: Measured hourly via a Foley catheter to ensure the kidneys are being adequately perfused.
• Pulmonary Capillary Wedge Pressure (PCWP): In some cases, to monitor the pressure in the heart's left atrium.
• Serum Lactate: To monitor for signs of systemic tissue hypoxia (lack of oxygen).

This medication is only used in hospitalized, critically ill patients. Patients receiving Dopamine will be confined to a bed and will not be in a condition to drive or operate machinery. Following recovery, the effects of Dopamine wear off within minutes, but the underlying condition (e.g., shock) will dictate the timeline for returning to normal activities.

Alcohol is strictly prohibited while a patient is in the acute state requiring Dopamine. Alcohol can worsen hypotension and interfere with the cardiovascular system's ability to respond to vasopressors. Furthermore, the combination of alcohol and catecholamines can increase the risk of cardiac arrhythmias.

Dopamine should never be stopped suddenly. When the patient's condition stabilizes, the infusion rate must be gradually decreased (tapered). Sudden withdrawal can lead to a rapid and dangerous drop in blood pressure (rebound hypotension).

> Important: Discuss all your medical conditions with your healthcare provider before starting Dopamine. In emergencies, your family or healthcare proxy should provide this information.

• Monoamine Oxidase Inhibitors (MAOIs): This is the most critical interaction. Drugs like phenelzine, tranylcypromine, or linezolid inhibit the enzyme that breaks down Dopamine. If a patient has taken an MAOI in the last 2-3 weeks, the effects of Dopamine are massively potentiated. This can lead to a fatal hypertensive crisis (dangerously high blood pressure). The dose of Dopamine in these patients must be reduced to at least one-tenth (1/10th) of the usual dose.

• Tricyclic Antidepressants (TCAs): Drugs like amitriptyline or nortriptyline can increase the cardiovascular response to Dopamine, potentially leading to severe hypertension or arrhythmias.
• Halogenated Anesthetics: Inhalation anesthetics (like halothane or cyclopropane) sensitize the heart muscle to the effects of catecholamines. Using Dopamine during or after the use of these gases significantly increases the risk of ventricular arrhythmias.
• Phenytoin: Intravenous administration of phenytoin while a patient is receiving Dopamine has been reported to cause sudden, severe hypotension (low blood pressure) and bradycardia (slow heart rate). If anticonvulsant therapy is needed, alternatives to phenytoin should be considered.

• Beta-Blockers: Drugs like propranolol or metoprolol antagonize (block) the cardiac effects of Dopamine. This means Dopamine will be less effective at increasing heart rate and contractility, but its alpha-adrenergic (vasoconstrictor) effects may become more pronounced, leading to high blood pressure with a slow heart rate.
• Alpha-Blockers: Drugs used for high blood pressure or prostate issues can block the vasoconstrictive effects of high-dose Dopamine, making it less effective at raising blood pressure.
• Diuretics: While Dopamine may initially increase urine output, the use of potent diuretics (like furosemide) can lead to dehydration, which complicates the management of shock.

Since Dopamine is administered intravenously in an ICU setting, food interactions are rarely a direct concern. However, patients who have recently consumed large amounts of foods high in tyramine (aged cheeses, cured meats, red wine) while on MAOIs would be at an even higher risk of hypertensive crisis if Dopamine is administered.

• St. John's Wort: May have mild MAOI-like activity and could potentially increase the effects of Dopamine.
• Ephedra / Ma Huang: Contains ephedrine, which can have additive effects with Dopamine, leading to dangerous increases in blood pressure and heart rate.
• Ergot Alkaloids: Using ergotamine (for migraines) with Dopamine can cause extreme vasoconstriction and increase the risk of gangrene.

Dopamine can interfere with certain laboratory tests:

• Urinary Catecholamines: Dopamine administration will naturally increase the levels of dopamine and its metabolites in the urine, which can lead to false-positive results for tumors like pheochromocytoma.
• Serum Glucose: Catecholamines can cause a transient increase in blood sugar levels (hyperglycemia) by stimulating the release of glucose from the liver.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. In emergency situations, ensure your medical records are available to the clinical team.

Dopamine must NEVER be used in the following circumstances:

1. 1Pheochromocytoma: This is a rare tumor of the adrenal gland that secretes large amounts of adrenaline and noradrenaline. Administering Dopamine to these patients can trigger a catastrophic and potentially fatal hypertensive crisis because the body's adrenergic system is already overstimulated.
2. 2Uncorrected Tachyarrhythmias: If a patient has a dangerously fast heart rate (like ventricular fibrillation or rapid atrial fibrillation) that has not been stabilized, Dopamine should not be started. Because Dopamine increases heart rate and irritability of the heart muscle, it can worsen these rhythms and lead to cardiac arrest.
3. 3Hypersensitivity: Known allergy to Dopamine or any components of the formulation, including sulfites.

These are conditions where the benefit of Dopamine must be carefully weighed against the risks:

• Occlusive Vascular Disease: Conditions such as atherosclerosis, Buerger's disease, or Raynaud's phenomenon. The vasoconstrictive effects of Dopamine can completely cut off circulation to the limbs in these patients.
• Acidosis or Hypoxia: If the patient's blood is too acidic or lacks oxygen, Dopamine is much less effective and more likely to cause dangerous arrhythmias. These metabolic issues must be corrected before or during Dopamine therapy.
• Hyperthyroidism: Patients with overactive thyroids are hypersensitive to catecholamines and may develop severe tachycardia.

Patients who are allergic to other catecholamines (like epinephrine or norepinephrine) should be monitored closely, though true cross-allergy is rare. The most significant cross-sensitivity concern involves sulfite sensitivity. Patients who have had severe reactions to wine, dried fruits, or other sulfite-containing products must be identified, as many Dopamine preparations contain sodium metabisulfite.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Dopamine. In an emergency, they will use clinical judgment based on the severity of your shock.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Dopamine in pregnant women. Animal reproduction studies have not been conducted. It is unknown whether Dopamine can cause fetal harm when administered to a pregnant woman or if it can affect reproduction capacity.

• Clinical Considerations: Dopamine should be used during pregnancy only if the potential benefit to the mother clearly outweighs the risk to the fetus. In cases of maternal shock, maintaining the mother's blood pressure is essential for fetal survival, making Dopamine a necessary life-saving intervention. However, it may cause uterine vasoconstriction, potentially reducing placental blood flow.

It is not known whether Dopamine is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Dopamine, a decision should be made whether to discontinue nursing or to discontinue the drug. In the acute settings where Dopamine is used, breastfeeding is typically paused until the mother is stabilized and the drug has cleared her system.

Dopamine is used in pediatric patients to support heart function and blood pressure, but its use is considered 'off-label' in terms of formal FDA approval for specific pediatric indications.

• Neonates: Newborns may have a different distribution of dopamine receptors. Some studies suggest they may require higher doses to achieve a pressor response, while others show they are more sensitive to the heart-rate-increasing effects.
• Growth and Development: There are no data on the long-term effects of Dopamine on growth and development in children.

Clinical studies of Dopamine did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects.

• Sensitivity: Elderly patients often have a higher prevalence of underlying heart disease and reduced baroreceptor sensitivity. They are more likely to develop arrhythmias and myocardial ischemia when given Dopamine.
• Renal Function: While Dopamine metabolism is not primarily renal, the general decline in organ function in the elderly requires more cautious dosing and slower titration.

In patients with pre-existing renal disease, Dopamine must be used with caution. Although 'low-dose' Dopamine was once used to protect the kidneys, large-scale trials (like the ANZICS trial) have shown that it does not prevent renal failure or the need for dialysis. In patients with severe renal impairment, monitoring for fluid overload is crucial, as Dopamine is administered in an IV solution.

The liver is a major site for the metabolism of Dopamine via the COMT enzyme. Patients with cirrhosis or acute liver failure may have a reduced capacity to clear the drug, leading to a more prolonged effect and a higher risk of toxicity. Doses should be titrated slowly based on real-time blood pressure response.

> Important: Special populations require individualized medical assessment. Your clinical team will adjust the treatment plan based on these factors.

Dopamine is a precursor of norepinephrine that acts as a potent agonist on several types of receptors. Its primary action is mediated through the stimulation of D1 and D2 dopaminergic receptors, Beta-1 (β1) adrenergic receptors, and Alpha-1 (α1) adrenergic receptors.

• Dopaminergic Action: Stimulation of D1 receptors in the renal and mesenteric vasculature increases intracellular cyclic AMP, causing vasodilation and increased blood flow.
• Beta-Adrenergic Action: Stimulation of myocardial β1 receptors increases calcium influx into cardiac cells, enhancing the strength of contraction (inotropy) and increasing the heart rate (chronotropy).
• Alpha-Adrenergic Action: Stimulation of α1 receptors on vascular smooth muscle leads to the activation of phospholipase C, increasing intracellular calcium and causing systemic vasoconstriction.

• Onset of Action: Within 5 minutes of starting the IV infusion.
• Duration of Action: Less than 10 minutes after the infusion is stopped.
• Dose-Response: The drug exhibits a 'classic' dose-response curve where low doses affect mainly the kidneys, medium doses affect the heart, and high doses affect the systemic blood vessels. However, there is significant overlap between these ranges in individual patients.

| Parameter | Value |

|---|---|

| Bioavailability | 0% (Oral), 100% (IV) |

| Protein Binding | Minimal |

| Half-life | ~2 minutes |

| Tmax | Immediate (IV infusion) |

| Metabolism | 75% via MAO and COMT in liver/kidney/plasma |

| Excretion | Renal (80% as metabolites within 24 hours) |

• Molecular Formula: C8H11NO2 (as Dopamine base); C8H11NO2·HCl (as Hydrochloride salt)
• Molecular Weight: 189.64 g/mol (Hydrochloride salt)
• Solubility: Freely soluble in water and soluble in alcohol.
• Structure: A phenethylamine consisting of a benzene ring with two hydroxyl groups (a catechol) and an ethylamine side chain.

Dopamine is a member of the Catecholamine class of sympathomimetic amines. It is therapeutically categorized as an Inotropic Agent and a Vasopressor. Related medications include Norepinephrine (Levophed), Epinephrine (Adrenalin), and Dobutamine (Dobutrex). Unlike Dobutamine, which is primarily a beta-agonist, Dopamine provides more significant alpha-adrenergic vasoconstriction at higher doses.